Zogenix and Battelle Expand DosePro Technology Business Agreement
Zogenix, Inc. and Battelle have entered into a new long-term collaborative agreement regarding co-marketing of Zogenix's DosePro(R) needle-free drug delivery technology, advancing potential out-licensing opportunities for DosePro with biopharmaceutical clients, and expanding the application of the technology to higher-dose biologic therapies.
The new five-year contract also establishes Battelle as the preferred provider of development services for the DosePro technology. Zogenix plans to leverage the substantial technical resources and capabilities of Battelle's drug delivery business for expertise in self-injection system design, human factors and device engineering as the companies further develop DosePro targeting dose volumes in excess of 1mL to accommodate a greater number of biopharmaceutical drug candidates.
The companies began co-marketing and product testing in March 2012, and the agreement builds on the success of the companies' relationship since then. During this period, the companies launched the "Less is More" marketing campaign, completed and presented studies supporting the use of DosePro with biologics, and presented patient research demonstrating preference for needle-free injection technology. The research, which queried 300 rheumatoid arthritis patients, demonstrated a significant 30 percent increase in patient acceptance of self-injected medication when a needle-free option was offered. In addition, the companies completed a study that demonstrated the ability of the DosePro technology to effectively deliver a monoclonal antibody therapeutic, AbbVie Inc.'s Humira(R) (adalimumab). The in vitro study showed that DosePro can deliver Humira without incremental risk to protein denaturation and equivalent biological integrity as compared to delivery by pre-filled syringe.
John Turanin, Vice President and General Manager, DosePro Technology, at Zogenix, said, "Through our co-marketing agreement with Battelle, we have expanded awareness of the DosePro needle-free drug delivery system. Battelle has proved to be a strong technical and business development ally and interest in the DosePro technology from biopharmaceutical companies has significantly increased because of Battelle's support. We are pleased with our progress and continue to believe there is significant potential to out-license DosePro for the delivery of biologics. Our new 5-year agreement with Battelle underscores both companies' commitment to achieving this goal, which includes executing on near-term and future opportunities."
"The DosePro technology offers the opportunity to solve major challenges in self-administration of important biologic therapies,"
added William Dunlevy, Vice President and General Manager, Process and Product Development at Battelle. "DosePro's advantages in delivery of highly viscous formulations and its attributes which support protein stability are unmatched by standard autoinjector technology, and offer valuable options to our biopharmaceutical clients."